# Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

> **NCT00024167** · PHASE3 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 265 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin hydrochloride
- **DRUG:** Estramustine phosphate sodium
- **DRUG:** Ketoconazole
- **DRUG:** Prednisone
- **DRUG:** Vinblastine
- **RADIATION:** Strontium chloride Sr 89
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00024167
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-04
- **Primary completion:** 2014-09
- **Final completion:** —
- **Target enrollment:** 265 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual
- **Last updated:** 2016-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00024167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00024167, "Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00024167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*